Member Info for bignose58

Morning The.Italian,

Further to my recent post where I ref Yooya (now known as Yooma) which ERP were looking to purchase (Entertainment Direct Asia Ltd (“Yooya”) ). I see that they have in fact started to make slow progress, although their current sp is still down a whacking 92%. Seems the CBD is much slower to take off than expected.

Yooma Wellness Inc - Toronto, Canada-based CBD and cannabis-related wellness products maker - In the third quarter that ended September 30, it records revenue of USD2.4 million, up 14% from USD2.1 million a year before. Attributes this to good growth from its operations in Europe and Japan. Also notes a benefit from acquisitions completed in the second half of 2021. Reports a net loss of USD624,821, narrowed from USD2.6 million. This can be put down to a "significant" reduction in expenses year-over-year, as the cost-cutting measures began implementing earlier this year are realised, Yoom says.

"We are continuing to explore different opportunities for a sale of assets, M&A or other strategic transactions and will update the market on the results of those efforts in due course," Chief Executive Jordan Greenberg comments.

Current stock price: CAD0.020, 12-month change: down 92%

Anyway, good luck in whatever path you choose to go down.

I totally agree with The.Italians last post, however. I would also add that the main concern for me is will they ever bring the product to market in the us, irrespective of any promises made in the prospectus since they have never been transparent and have constantly made dubious statements about timelines. Fortunately the Chinese approval process is being handled and paid for by a third party although as I wrote, that is now at the mercy of the Chinese dictators concessions on lockdowns which could last for years as COVID is here to stay.

It’s very difficult to be bullish when the company keeps letting its shareholders down with misleading and fake news…

Ripely,

JM is a billionaire and invests using his petty cash. A few AIM companies he invested in and had control of have gone tit-s up. They have written that he is the uk buffet, yet. Buffet makes money for his investors, big and small. JM doesn’t. He even lets his mates down too.

That’s also not forgetting the arrest warrant that was issued for him in South Korea for supposed market manipulation. Granted, it’s now past it’s sell by date, but he never went back to defend himself. My understanding is that another, local person, who was involved took the rap, although it was several years ago.

I wouldn’t trust him as far as I could throw him. He doesn’t even know the difference between a Gibson les Paul sold body electric guitar and a normal acoustic guitar…but that’s another story….. lol

Morning The.Italian, thanks for the support.

Yes, it certainly makes for depressing reading and yet, I only really scratched the surface. I didn’t even mention the Ozzy tax debacle where the company employed tax advisers who advised no liability which the company supported and advised shareholders of such facts. Then capitulated and settled out of court. Even though they paid a smaller amount, they still effectively admitted liability by way of a 9mill payment!!!

As you say lucky for the legacy investment paid for their capitulation. It could have paid for the phase iii trials which I am sure could still be problematic if no us licensee comes forward.

continued....

The 0.065 drops you discuss are most likely due to.
1. the company wanted to purchase Yooya (a cannabis associated company) which luckily for shareholders never went through (the sp at the time dropped because of this). It soon jumped back up once it was announce it would not happen. At the time they even stated they had a "concrete" alternative cannabis investment and would keep shareholders informed. This never happened and it would appear the concrete was just left to set... :-)

2. Over a year later they purchased the DLI which is associated with Longevity and is currently a white elephant (At the time it was all a bit suspect since they announced later they were looking to purchase a company in May of that year for around 3.79mill usd yet the DLI had only gotten a first round of investment (from other entities) of 3,79mill usd according to the media in June/July). How was that possible and how was it possible that those involved in the first investment round would accept the same amount??? Surely they would want more ??? Again, the SP was driven down to the same 0.065 level and eventually existing shareholders were diluted by 23%. A week before the announcement the sp jumped nearly 100%. The company also had news from an EU OTC approval which they deliberately held back. since in my opinion they wanted to have a low sp so they could give the DLI shareholders more shares in ERP.

Interestingly, at the time the company value dropped to around 15mill squid, which was amazing given the CEO had a yearly salary of 1.5mill USD !!!

Furthermore, the company made a 3mill GBP investment in the Diabetic Boot Company which went tit_s-up in 3 years (this was their only investment where cas was used, but also wasted. The Chairman who initiated the investment and was himself invested heavily bought RPGs investment for 270K.

I stay invested, like a few other longtermers, because ERP should soon obtain Chinese approval (depending on how their draconian Covid policies pan out) and eventual FDA approval.

But do not be fooled by the rubbish that is written on the ERP website since they have proven time and time again, they know nothing about nothing. ;-)

All of this is within the ERP announcement documents, apart from any PLE info which is no longer available, although I do have copies of most of their announcements (RNS's) .

If anyone else has anything to add (or any corrections) as I have only touched the surface/

Ripley, to fill you in a bit more.

I don't think I am wrong in writing that most LTH's invested because of the prospects associated with the Fortacin PE product, however. Due to huge amounts of incompetence by an inexperienced BOD and CEO (they are all the originals from when the company was a mining investment company - There is not one person amongst them with any knowledge of pharma or commercialisation of pharma products).
In March 2014 (when PRG now ERP CEO took over the reins) there was a PLE announcement called "Unambiguous FDA way forward" (or something to that effect) whereby they stated approval would be obtained mid 2017. Although there was a complete ****up with trying to reduce the original 20 dose can to 6 doses which gave a delay of 9 months which meant they should have received approval in the latter half of 2018, it was obviously complete BS since here we are 4+ years on and still no approval. They never did provide any reason why the unambiguous way forward increased by many years and they never provided any reason why licensees at the time who were stated to be at heads of terms walked away. I cannot believe there was any such agreement given we are now 4+ years past their scheduled approval window and they are still making excuses.

When PLE was bought out, shareholders, were issued with shares in RPG with a 35% dilution and the value of the company(PLE) was at 0.95 HK$/share. Since then PLE shareholders have witnessed a total dilution of around 85 to 90% of their holding as well as a 92% drop in share price to todays figure. RPG/ERP have never actually bought a company from cash reserves, they have only ever issued more shares which always gets approved since the Chairman/CEO/bod and their hangers on own around 45% (this will soon be increased to around 60% with this next round since they all receive preferential share purchase opportunities).

..... continued

Ripley,

The rights issue may only be applicable to HK. They may not be offered to anyone outside - see page 16 of the below.

http://www.endurancerp.com/ICMServlet/download/13-2625-4265/ew_00575Ann-26092022.pdf

This board has had constant chat. Granted, there have been a few days of no posts, but this is now due to the recent rights issue which has given cause (in my opinion) to the company withholding price sensitive information from the market and shareholders. Such as, Manufacture approval for Europe OTC. US FDA phase II results meeting (scheduled for Oct) leading to continuation on to phase III start. Marketing approval for Singapore (approved in July !!!) and China completion of the phase III (scheduled for completion in Oct).

It would also seem that since the orchestrated drop in sp to the rights issue price the M&Ms are keeping the sp at the current level by way of 10k (single lot) trades. Note: The share price was around 0.15 for many weeks, yet they suddenly decided to have a rights issue at 0.07. Interestingly exactly the same modus operandi as the DLI purchase a year or so back.

All my own opinion of course....... but seems pretty obvious.

Morning The.Italian,
Only time will tell I’m afraid. It’s anyones guess what the company is up to or not up to these days.

Given the current climate in China, I cannot help but feel delays on the approval process and marketing/sales are going to be a long and painful time. So back to what comes first the FDA => sales or China => sales. Answers on a postcard and sent to ERP before the end of the world......lol...gulp.

Morning the.Italian.

That's because it would be too easy for them, They certainly don't have any business acumen to help the company or increase shareholder value. Amazing given the DLI was meant to be JGs baby who seems to have no interest/motivation in getting anything to market. Any good CEO would be more hands on and would be out there pushing the product whenever and wherever they can. Far too many years sitting behind a desk watching mining stocks has left its mark.

Jim certainly makes some stupid statements.......10 years is typically less than one eighth of your lifespan..........

Thats when a person is just born !!!!

No mention of the approval though..... :-O

Recordati have just uploaded their interims for the last nine months.

Although they do include Fortacin within their contributory OTC products (total group sales up 16% to 230mill Euros), I have my doubts they have sold anything given they only recently received change in manufacturer approval and ERM themselves stated sales wouldn't commence till next year. Mind you. nothing to say they may have sold a can or two... :-)

https://www.recordati.com/en/investors/annual_and_interim_reports/

Morning The.Italian.

I guess its a bit like Regent changing their name. They think it will attract investors........not :-)

Its interesting the way it is written. Its as if they have not had any discussions with with any of the listed bodies. It also reads a bit like one of those market stall sellers in London....Delboy comes to mind. I wonder if the App responds in Chinese like some of the dolls Delboy was trying to offload....lol

We're not asking 10 pounds as that would make us look greedy. We're not even gonna ask for 5 pounds as that would give the impression we know what we're talking about, but for this day only, we will let you have it at the knockdown price of 1 pound. In fact. Just for today, we will pay you 1 pound to take it off our hands.....lol

I’m pretty sure they won’t announce anything until after the rights issue otherwise they could be putting themselves on the spot if the sp increases well above the proposed placing price. Particularly since they still have 2 months to go before it all happens. This could also give reason for current shareholders to take up their rights. The company could be using the withholding of news as leverage to get more money.
All in my opinion of course, but I wouldn’t put it past them.

:-)

Hi Prof,

Far be it for me to make any suggestion, but it might be worth considering waiting for another 6 months since we should have come close to crossing the line in China (I don't expect too much of a delay, if any, apart from their own C19, antics) given ERP is not handling it so it won’t go tits up. And we should have at least started the phase iii, which given ERPs historic handling may take another year or two, to complete, however. There is a good chance the China approval will result in some income. Both these contributions to news should lift the sp so if you wanted to offload, you would at least get more for the shares than today.

I don’t think you have much to lose now, although the sp could drop further once the rights shares hit the market (approx 50% dilution), but this may not be the case since the value before the recent drop to the rights sp, was double the current value and with the rights shares in play, it may just go back to that value and then possibly on from there.

Just my opinion, however. But good luck whatever you decide.